Genmab — September 2017

[bibob]

Rod med IPAD. Ved ikke om linkene virker.

[bibob]

https://cslide.ctimeetingtech.com/library/esmo/browse/search/Kop#2Bb3g0jp

[Mogan]

bibob: tak, de virker hos mig

[Helge_LarsenPI-redaktør]

God morgen og tak for link.

[bibob]

[JKY_VH]

God morgen og tak bibob

[E_L]

aren't these the same links as we discussed on Thursday morning?

[bibob]

I really dont know. Just seeing them

[E_L]

no worries bibob, better too often as not at all;
enjoy you coffee in the sun

[E_L]

Cellectis Reports Clinical Hold of UCART123 Studies http://www.businesswire.com/news/home/20170904005410/en/

[Jedi]

More on UCART from Celletics http://www.cellectis.com/en/products/ucarts/ apparently, the next generation CAR-T is not quite ready yet...

[Jedi]

The Cellectis UCART123 target CD123, different from the fatalities of CAR-T targeting CD19, but same sad result

[Sukkeralf]

But we also saw Janssen/Genmab having problems with CD123/CD3 - probably not easy to engage the T-cell and av
oid adverse effects

[Sukkeralf]

But offcause with the bispecific CD3 antibodies you can stop giving the drug - thats the problem with CAR-T

[Bulder]

Det er vel ikke target cd19/cd123, der er årsagen til cytokin-stormen?

[Sukkeralf]

Cytokine release syndrome - Wikipedia

(en.wikipedia.org)

[Bulder]

tak. Som jeg forstår det er cytokin-stormen en (uheldig) egenskab ved t-cellen og uafhængig af hvilket target den binder sig til?

[bibob]

T-celle terapi er langt fra i mål. Patienter med samme diagnoser responderer jo forskelligt på samme behandling. Det ER et svært område at navigere i.

[Sukkeralf]

Bulder - enig. Bibob det gør patienter jo også ved alle mulige andre behandlinger.

[E_L]

good comment at 09.29... Blindingly obvious & very important problem for car-t, but I hadn't even thought of it that way
...